The hemodialysis (HEMO) study: Rationale for selection of interventions

Seminars in Dialysis

Volumn 9, Issue 1, 1996, Pages 24-33

  Eknoyan, Garabed ^a   Levey, Andrew S ^b   Beck, Gerald J ^b   Agodoa, Lawrence Y ^b   Daugirdas, John T ^b   Kusek, John W ^b   Levin, Nathan W ^b   Schulman, Gerald ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002661706     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-139x.1996.tb00897.x     Document Type: Article

References (54)

1. Kidney Failure and the Federal Government. Washington, National Academy Press, 1991
2. Proceedings from the Morbidity, Mortality and Prescription of Dialysis Symposium, Dallas, TX, September 15-17, 1989. American Journal of Kidney Diseases 15:357-383, 1990
3. Lowrie EG, Laird NM, Parker TF, Sargent JA: Effect of the hemodialysis prescription on patient morbidity: Report from the National Cooperative Dialysis Study. New Eng J Med 305:1176-1180, 1981
4. Keshaviah P: Urea kinetic and middle molecule approaches to assess adequacy of hemodialysis and CAPD. Kidney Int 43 (Suppl. 40):S28-S38, 1993
5. Hakim RM, Breyer J, Ismail N, Schulman G: Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 23:661-669, 1994
6. Parker TF, Husni L, Huang W, Lew N, et al.: Survival of hemodialysis patients in the United States is improved with a greater quantity of dialysis. Am J Kidney Dis 23:670-680, 1994
7. Collins AJ, Ma JZ, and Umen A: Urea index (Kt/V) and other predictors of hemodialysis patient survival. Am J Kidney Dis 23:272-282, 1994
8. Charra B, Calemard E, Ruffet M, et al.: Survival as an index of adequacy of dialysis. Kidney Int 41:1286-1291, 1992
9. Kopple JD, Hakim R, Held P, Keane W, King K, Lazarus JM, Parker TF, Teehan BP: Recommendations for reducing the high morbidity and mortality of U.S. maintenance dialysis patients. AJKD 24:968-973, 1994
10. Renal Data System: USRDS 1995 Annual Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, July, 1995
11. Kidney Disease Program Analysis: A Report to the Surgeon General. U.S. Department of Health and Human Services. Public Health Service Publication Number 1745. Washington, D.C., 1967
12. Striker GE, Scherbenske MJ (eds.); Proceedings from the Workshop on the Morbidity and Mortality of End-Stage Renal Disease. Am J Kid Dis 21:71-120, 1993
13. MMHD Study Group (prepared by Levin NW, Agodoa LY, Gassman JG, Heyka RJ, Kaufman AM, Keen ML): Comparisons of Smye algorithm with double pool model solutions for estimating (eKt/V). Am Soc Nephrol 5:519, 1994
14. MMHD Study Group (prepared by Eknoyan G, Beck GJ, Breyer J, Kopple JD, Kusek JW, Levey AS, Striker GE): Design and preliminary results of the Mortality and Morbidity of Hemodialysis (MMHD) pilot study. J Am Soc Nephrol 5:413, 1994
15. Johnson WJ, Hagge WW, Wagoner RD, Dinapoli RP, Rosevear JW: Effects of urea loading in patients with far-advanced renal failure. May Clin Proc 47:21-29.12, 1972
16. Gotch FA, Sargent JA: A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 28:526-534, 1985
17. Owen WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM: The Urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Eng J Med 329:1001-1006, 1993
18. Daugirdas JT, Schneditz D: Overestimation of hemodialysis dose (delta Kt/V) depends on dialysis efficiency (K/V) by regional blood flow and conventional 2-pool urea kinetic analyses. ASAIO J in press, 1995
19. Nakamato M et al.: Long term controlled study of high flux versus cellulose membrane on the incidence of dialysis related amyloidosis. J Am Soc Nephrol 2:340, 1991
20. Josephson MA et al.: Improved lipid profiles in patients undergoing high flux hemodialysis. Am Kidney Dis 20:361-366, 1992
21. Depner T et al.: Effectiveness of low dose EPO: Advantage of high flux hemodialysis. ASAIO J M223-225, 1990
22. Saito et al.: Separation of an inhibitor of erythropoiesis in middle molecules from patients with chronic renal failure. Clin Chem 21: 1938-1941, 1986
23. Sherman RA, Daniel A, Cody RP: The effect of interdialytic weight gain on predialysis blood pressure. Artificial Organs 17:770-774, 1993
24. Charra B: Does empirical long slow dialysis result in better survival? ASAIO 39:819-821, 1993
25. Held PJ, Levin NW, Bovberg RR, Pauly MF, Diamond LH: Mortality and duration of hemodialysis treatment. JAMA 265:871-875, 1991
26. Port F: personal communication, 1995
27. Tokars JI, Alter MJ, Favero MS: National surveillance of dialysis associated disease in the United States, 1993. HHS Centers for Disease Control and Prevention, 9-12, 1994
28. Kaufman AM, Frinak S, Godmere RO, Levin NW: Clinical experience with heat sterilization for reprocessing dialyzers. ASAIO J 38:M338-M340, 1992
29. Garred LJ, Canaud B, Flavier JL, Poux C, Polito-Bouloux C, Mion C: Effect of reuse on dialyzer efficacy. Artif Organs 14:80-84, 1990
30. 2-microglobulin removal using polysulfone membranes. Am J Kidney Dis 21:405-410, 1993
31. Goldman M, Lagmiche M, Dhaene M, Amraoui Z, Thayse C, Vanherweghem JL: Adsorption of beta 2-microglobulin on dialysis membranes: Comparison of different dialyzers and effects of reuse procedures. Int J Artif Organs 12:373-378, 1989
32. Ken PG, Argiles A, Canaud B, Flavier JL, Mion C: The effects of reprocessing high-flux polysulfone dialyzers with peroxyacetic acid on beta 2-microglobuline removal in hemodiafiltration. Am J Kidney Dis 19:433-438, 1992
33. Chenoweth DE, Cheung AK, Ward DM, Henderson L: Anaphylatoxin formation during hemodialysis: Comparison of new and re-used dialyzers. Kidney Int 24:770-774, 1983
34. Dumler F, Zasuwa G, Levin NW: Effect of dialyzer reprocessing methods on complement activation and hemodialyzer-related symptoms. Artif Organs 11:128-131, 1987
35. Hakim RM, Levin N: Malnutrition in hemodialysis patients. Am J Kidney Dis 21:125-137, 1993
36. Churchill DN, Taylor DW, Cook RJ, LaPlante P, Barre P, Cartier P, Fay WP, Goldstein MB, Jindal K, Mandin H, McKenzie JK, Muirhead N, Parfrey PS, Posen GA, Slaughter D, Ulah RA, Wer R: Canadian hemodialysis morbidity study. Am J Kidney Dis 3:214-234, 1992
37. Kopple JD, Berg J, Hauser H, Steinman TI, Teschan PE: Modification of Diet in Renal Disease (MDRD) Study Group. Nutritional status of patients with different levels of chronic renal insufficiency. Kidney Int 36(Suppl. 27):S-184-S-194, 1989
38. Rostand SG, Brunzell JD, Cannon RO, et al.: Cardiovascular complications in renal failure. J Am Soc Neph 2:1053-1062, 1991
39. Parfrey PS, Harnett JD, Barre PE: The natural history of myocardial disease in dialysis patients. J Am Soc Neph 2:2-12, 1991
40. Appel G: Lipid abnormalities in renal disease. Kidney Int 39:169-183, 1991
41. Collins AJ, Hanson G, Umen A, et al.: Changing risk factor demographics in end-state renal disease patients entering hemodialysis and the impact on long-term mortality. Am J Kidney Dis 15:422-432, 1990
42. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Eng J Med 325:293-302, 1991
43. Acosta JH: Hypertension in chronic renal disease. Kidney Int 22:702-712, 1982
44. Pegues DA, Beck-Sague CM, Woollen SW, et al.: Anaphylactoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE inhibitors. Kidney Int 42:1232-1237, 1992
45. Haire HM, Sherrard DJ, Scardapane D, et al.: Smoking, hypertension, and mortality in a maintenance dialysis population. Cardiovas Med 1163-1168, 1978
46. Rao TKS, Roxe DM, Laird NM, et al.: Hemodynamic and cardiac correlates of different hemodialysis regimens: NCDS. Kidney Int 23(suppl 13):S89, 1983
47. Cheigh J, Bui D, Milite C, et al.: How well is hypertension (H) controlled in hemodialysis patients. J Am Soc Neph 1:351, 1990
48. Baumgart P, Walger P, Gemen S, et al.: Blood pressure elevation during the night in chronic renal failure, hemodialysis and after renal transplantation. Nephron 57:293-298, 1991
49. 1988 Joint National Committee: The 1988 report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Med 148:1023-1038, 1988
50. Grundy SM: Management of hyperlipidemia of kidney disease. Kidney Int 37:847-353, 1990
51. Consensus Conference, Grundy SM, Barrett-Connor E, Bierman EL, et al.: Treatment of hypertriglyceridemia. JAMA 251:1196-1200, 1984
52. National Cholesterol Education Program: Report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 148:36-39, 1988
53. Pasternack A, Vanttinen T, Solakivi T, et al.: Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure. Clin Nephrol 27:163-168, 1987
54. Wanner C, Horl WH, Luley CH, Wieland H: Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int 39:754-760, 1991